Northern Trust’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $59.9M | Buy |
674,529
+95,622
| +17% | +$6.98M | 0.01% | 1091 |
|
|
2026
Q1 | $29.2M | Buy |
578,907
+17,884
| +3% | +$674K | ﹤0.01% | 1449 |
|
|
2025
Q4 | $18.4M | Buy |
561,023
+118,987
| +27% | +$3.11M | ﹤0.01% | 1718 |
|
|
2025
Q3 | $7.41M | Buy |
442,036
+5,089
| +1% | +$83K | ﹤0.01% | 2278 |
|
|
2025
Q2 | $6.54M | Buy |
436,947
+57,072
| +15% | +$844K | ﹤0.01% | 2316 |
|
|
2025
Q1 | $6.13M | Buy |
379,875
+30,892
| +9% | +$643K | ﹤0.01% | 2313 |
|
|
2024
Q4 | $8.12M | Buy |
348,983
+34,693
| +11% | +$1.02M | ﹤0.01% | 2240 |
|
|
2024
Q3 | $9.24M | Buy |
314,290
+228,702
| +267% | +$6.37M | ﹤0.01% | 2110 |
|
|
2024
Q2 | $2.01M | Buy |
85,588
+19,248
| +29% | +$649K | ﹤0.01% | 2896 |
|
|
2024
Q1 | $2.52M | Buy |
+66,340
| New | +$1.92M | ﹤0.01% | 2848 |
|
|
2023
Q3 | – | Sell |
-3,917
| Closed | -$44.1K | – | 4523 |
|
|
2023
Q2 | $44.1K | Hold |
3,917
| – | – | ﹤0.01% | 4246 |
|
|
2023
Q1 | $28.4K | Buy |
3,917
+460
| +13% | +$5.05K | ﹤0.01% | 4379 |
|
|
2022
Q4 | $38.9K | Buy |
3,457
+689
| +25% | +$12.4K | ﹤0.01% | 4343 |
|
|
2022
Q3 | $36K | Hold |
2,768
| – | – | ﹤0.01% | 4413 |
|
|
2022
Q2 | $35K | Sell |
2,768
-10,582
| -79% | -$371K | ﹤0.01% | 4511 |
|
|
2022
Q1 | $768K | Sell |
13,350
-638
| -5% | -$53.6K | ﹤0.01% | 3551 |
|
|
2021
Q4 | $1.66M | Sell |
13,988
-640
| -4% | -$101K | ﹤0.01% | 3316 |
|
|
2021
Q3 | $2.91M | Sell |
14,628
-106
| -0.7% | -$18.5K | ﹤0.01% | 3075 |
|
|
2021
Q2 | $2.56M | Sell |
14,734
-3,319
| -18% | -$603K | ﹤0.01% | 3239 |
|
|
2021
Q1 | $3.57M | Sell |
18,053
-1,170
| -6% | -$224K | ﹤0.01% | 2949 |
|
|
2020
Q4 | $3.78M | Buy |
19,223
+357
| +2% | +$74K | ﹤0.01% | 2839 |
|
|
2020
Q3 | $3.35M | Sell |
18,866
-1,091
| -5% | -$202K | ﹤0.01% | 2772 |
|
|
2020
Q2 | $4.62M | Buy |
19,957
+8,106
| +68% | +$1.54M | ﹤0.01% | 2573 |
|
|
2020
Q1 | $1.38M | Buy |
11,851
+102
| +0.9% | +$17.3K | ﹤0.01% | 3057 |
|
|
2019
Q4 | $2.24M | Sell |
11,749
-340
| -3% | -$66.7K | ﹤0.01% | 3054 |
|
|
2019
Q3 | $2.32M | Buy |
12,089
+2,704
| +29% | +$527K | ﹤0.01% | 3017 |
|
|
2019
Q2 | $1.61M | Buy |
9,385
+747
| +9% | +$129K | ﹤0.01% | 3177 |
|
|
2019
Q1 | $1.74M | Buy |
8,638
+1,328
| +18% | +$277K | ﹤0.01% | 3160 |
|
|
2018
Q4 | $1.37M | Buy |
7,310
+37
| +0.5% | +$7.85K | ﹤0.01% | 3251 |
|
|
2018
Q3 | $1.74M | Buy |
7,273
+186
| +3% | +$43.4K | ﹤0.01% | 3279 |
|
|
2018
Q2 | $1.87M | Buy |
7,087
+6,356
| +869% | +$1.56M | ﹤0.01% | 3235 |
|
|
2018
Q1 | $181K | Buy |
731
+71
| +11% | +$12.8K | ﹤0.01% | 3848 |
|
|
2017
Q4 | $89K | Hold |
660
| – | – | ﹤0.01% | 3994 |
|
|
2017
Q3 | $81K | Hold |
660
| – | – | ﹤0.01% | 3996 |
|
|
2017
Q2 | $64K | Hold |
660
| – | – | ﹤0.01% | 4048 |
|
|
2017
Q1 | $123K | Buy |
+660
| New | +$93.2K | ﹤0.01% | 3912 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
Northern Trust's SYRE Position: Q2 2026 in Review
Northern Trust increased its Spyre Therapeutics (SYRE) stake by 17% in Q2 2026, buying an estimated $6.98M and bringing the position to 674,529 shares worth $59.9M. The position accounts for 0.01% of the portfolio, ranked #1091.
Northern Trust first reported a position in SYRE in Q1 2017 and has held it in 36 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- Northern Trust held 674,529 shares of Spyre Therapeutics worth $59.9M as of Q2 2026.
- Northern Trust bought 95,622 Spyre Therapeutics shares in Q2 2026, an estimated $6.98M.
- Spyre Therapeutics made up 0.01% of Northern Trust's portfolio in Q2 2026, its #1091 holding.
- Northern Trust first reported a position in Spyre Therapeutics in Q1 2017 and has held it in 36 quarters since.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.